EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
about
Metabolic aspects of adult patients with nonalcoholic fatty liver diseaseCardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective studyCo-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review articleFatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIVPediatric Nonalcoholic Fatty Liver Disease: the Rise of a Lethal Disease Among Mexican American Hispanic Children.Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease.Transient elastography as a screening tool for liver fibrosis in a large hemodialysis populationAssociation of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis CUsing controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study.Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease.Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should doNon-alcoholic fatty liver disease: An expanded reviewNonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis.A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver DiseaseToxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALDNonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver DiseaseDevelopment of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia.Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern.Alcohol and Steatosis: The Japanese ParadoxEffects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis.Clinical guidelines of non-alcoholic fatty liver disease: A systematic review.Independent effects of diet and exercise training on fat oxidation in non-alcoholic fatty liver disease.Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging.Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat.Acylated and desacyl ghrelin are associated with hepatic lipogenesis, β-oxidation and autophagy: role in NAFLD amelioration after sleeve gastrectomy in obese rats.The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease.Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional studyA noninvasive diagnostic model to assess nonalcoholic hepatic steatosis in patients with chronic hepatitis B.Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patientsAltered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance.Absorption, Distribution, Metabolism, and Excretion of [(14)C]-Volixibat in Healthy Men: Phase 1 Open-Label Study.Enhanced liver fibrosis test as a reliable tool for assessing fibrosis in nonalcoholic fatty liver disease in a clinical setting.Type 1 Diabetes and Non-Alcoholic Fatty Liver Disease: When Should We Be Concerned? A Nationwide Study in Brazil.Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study.The future of diagnosing NASH - could a simple blood test be the key?Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD.
P2860
Q28067490-E976893C-5AB9-4A7A-9071-315C00E9EE91Q28074308-4D2D5D05-0806-4064-B38E-5DF92BD45FB1Q28076892-A0128349-24F4-410A-9241-9C00F069FF14Q28079826-D80DF19D-6C8B-4667-834D-6484004D557AQ30241654-B0198C30-BB45-4E53-B6AB-B6FC912AD2C8Q30355958-DC425F38-CE45-4257-BB8A-064225EE5A4DQ33577504-C598EA0E-E7FE-4E4B-98B5-B10C6132F809Q33582978-7DB9D9F9-D7B2-4504-BBF0-96DD42B16E0DQ33584964-E61E2745-991F-4EAE-8914-0F71CEDE99E1Q33652021-5E503A89-20EF-4024-A1D6-FD0465AA8386Q33716191-A0CEC401-AAEC-4D51-8406-E89A55416E30Q33789868-079B50B9-D337-49D0-B237-7CBCDB0DEFC6Q33805278-1DCD8058-F181-4A0A-9F53-9A0BE87F1EE1Q33838454-B8F656EF-4A5C-4945-9019-772D993C76AFQ33852213-86083B09-8CFD-476C-8836-B4C72A088105Q33855157-5C2E98C2-3198-4FDB-AD67-E2C7A7E2D790Q33866766-CEB2F5F9-DBB1-4340-A767-2E0E0FF830FDQ36138443-19E866E6-1EF8-49D3-9072-55F19C171FEDQ36218142-74DDDD57-CD7C-4DA6-A67D-439523D89B2AQ36405031-A2A695D0-6EB5-42E3-8008-9371B5F2AD2AQ37003731-56D4631E-FB93-41BA-9A9A-CC137052B0B7Q37034826-0C5D4200-4818-4AC9-91D5-FF0082E88B75Q37249919-58E57D49-08D5-4A93-82CA-CA8E6B4BE5B0Q37284519-7F50AAD9-FA80-475F-BE7E-466A38EBB306Q37285170-19A53826-AE8B-4410-8F7A-CF6669CC8816Q37312166-70677FE7-2BFF-447A-854B-A197355EB954Q37444289-3B82389D-25E6-49A7-90D1-46D5C1AFAB66Q37501044-1447A766-931A-47E2-9AA9-03AAF7DC025EQ37529340-02C5107C-9E26-4377-8C36-FDFC44570297Q37595709-5AC6903C-F6E2-4F11-A7CD-FF9C938557DBQ37612102-E43F7CDD-3BB1-4C34-84BF-FFDF49159038Q37632267-68FB164C-417A-4154-A8E2-CCB53F1DC876Q37703523-F6BE5832-7A9C-411B-997B-73303FB51D4DQ38287516-5C9C9FC8-3005-4F86-9329-78DA549A535AQ38374046-FA30B6CF-4685-43F6-A140-A0E163CEAC57Q38598029-3865E9C4-3749-4317-B2E7-2BBBE7905A66Q38623900-E4A00254-F110-4214-9377-EB54757E3A7BQ38626156-8D0C9953-15E4-4129-9ECF-A26CCF0E32DBQ38634380-BA3DF798-B061-4176-8400-8B2743828751Q38655966-4DFE0EFD-2768-4123-A1C0-DB965803F882
P2860
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@ast
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@en
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@nl
type
label
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@ast
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@en
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@nl
prefLabel
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@ast
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@en
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@nl
P2093
P1476
EASL-EASD-EASO Clinical Practi ...... alcoholic fatty liver disease.
@en
P2093
European Association for the Study of Diabetes (EASD)
European Association for the Study of Obesity (EASO)
European Association for the Study of the Liver (EASL)
P304
P356
10.1016/J.JHEP.2015.11.004
P577
2016-03-10T00:00:00Z